Qian Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qian Shen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Hao Yang
Department of Pathophysiology, School of Medicine, Nantong University, Nantong
1 shared publicationHuinan Wang
Medical School of Nantong University, Affiliated Tumor Hospital of Nantong University
1 shared publicationJie Zhang
Department of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong
1 shared publication- Lei Yang
Department of Oncology, Affiliated Tumor Hospital of Nantong University
1 shared publication Min Chen
Medical School of Nantong University, Affiliated Tumor Hospital of Nantong University
1 shared publicationXiaobing Miao
Department of Pathology, Affiliated Tumor Hospital of Nantong University, Nantong
1 shared publication
Latest Publications
- Open Access
- 22 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1907503
A palmitoylation-related signature predicts prognosis and immune microenvironment features in diffuse large B-cell lymphoma
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma and remains highly heterogeneous in prognosis. Palmitoylation, an important post-translational modification, has been implicated in tumor biology, but its role in DLBCL, particularly in relation to the immune microenvironment, remains unclear. Methods: Transcriptomic and clinical data from 706 patients with DLBCL were obtained from the Gene Expression Omnibus database. Prognosis-associated palmitoylation-related genes were identified by differential expression and univariate Cox regression analyses. An optimal prognostic model was developed by comparing 101 machine learning algorithm combinations and was further integrated with clinical variables to construct a nomogram. The tumor immune microenvironment was evaluated using immune infiltration, immune function, immune checkpoint, and Tumor Immune Dysfunction and Exclusion analyses. Weighted gene co-expression network analysis (WGCNA) and Mendelian randomization (MR) were performed to identify key genes, followed by experimental validation. Results: A 33-gene palmitoylation-related signature (PRS) was established and evaluated across multiple cohorts. PRS was an independent prognostic factor of DLBCL and showed consistent prognostic performance across datasets. Low-risk patients showed higher immune cell infiltration and more active immune function, whereas high-risk patients showed a greater predicted potential to respond to immune checkpoint inhibitor therapy. A nomogram integrating PRS with clinical characteristics also showed favorable predictive accuracy. In addition, two palmitoylation-related molecular subtypes with distinct transcriptomic features, survival outcomes, and immune microenvironment characteristics were identified in DLBCL. CEACAM3 was prioritized as a key candidate gene based on integrated WGCNA and MR analyses, and functional experiments showed that CEACAM3 knockdown suppressed proliferation and invasion and promoted apoptosis, whereas CEACAM3 overexpression enhanced proliferation and invasion, reduced apoptosis, and promoted tumor growth. Conclusion: The PRS captures prognostic heterogeneity and distinct immune microenvironment features in DLBCL. PRS may provide a useful tool for risk stratification, and CEACAM3 may serve as a potential biomarker and therapeutic target in DLBCL.
- 22 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1907503
Open AccessA palmitoylation-related signature predicts prognosis and immune microenvironment features in diffuse large B-cell lymphoma
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma and remains highly heterogeneous in prognosis. Palmitoylation, an important post-translational modification, has been implicated in tumor biology, but its role in DLBCL, particularly in relation to the immune microenvironment, remains unclear. Methods: Transcriptomic and clinical data from 706 patients with DLBCL were obtained from the Gene Expression Omnibus database. Prognosis-associated palmitoylation-related genes were identified by differential expression and univariate Cox regression analyses. An optimal prognostic model was developed by comparing 101 machine learning algorithm combinations and was further integrated with clinical variables to construct a nomogram. The tumor immune microenvironment was evaluated using immune infiltration, immune function, immune checkpoint, and Tumor Immune Dysfunction and Exclusion analyses. Weighted gene co-expression network analysis (WGCNA) and Mendelian randomization (MR) were performed to identify key genes, followed by experimental validation. Results: A 33-gene palmitoylation-related signature (PRS) was established and evaluated across multiple cohorts. PRS was an independent prognostic factor of DLBCL and showed consistent prognostic performance across datasets. Low-risk patients showed higher immune cell infiltration and more active immune function, whereas high-risk patients showed a greater predicted potential to respond to immune checkpoint inhibitor therapy. A nomogram integrating PRS with clinical characteristics also showed favorable predictive accuracy. In addition, two palmitoylation-related molecular subtypes with distinct transcriptomic features, survival outcomes, and immune microenvironment characteristics were identified in DLBCL. CEACAM3 was prioritized as a key candidate gene based on integrated WGCNA and MR analyses, and functional experiments showed that CEACAM3 knockdown suppressed proliferation and invasion and promoted apoptosis, whereas CEACAM3 overexpression enhanced proliferation and invasion, reduced apoptosis, and promoted tumor growth. Conclusion: The PRS captures prognostic heterogeneity and distinct immune microenvironment features in DLBCL. PRS may provide a useful tool for risk stratification, and CEACAM3 may serve as a potential biomarker and therapeutic target in DLBCL.
- Open Access
- 2 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1944126
Tumor-associated macrophages in gastric cancer peritoneal metastasis: orchestrating immune evasion, niche remodeling, and therapeutic resistance
Peritoneal metastasis is the most devastating form of progression of gastric cancer, characterized by strong immune suppressive properties and resistance to treatment. Tumor-associated macrophages (TAMs) are the main population of immune cells in the peritoneal cavity and participate in nearly every step of this process. In this Review, we focus on the two major origins of peritoneal macrophages (embryonic-derived GATA6+ resident cells and monocyte-derived CCR2+ cells), and we describe how gastric cancer cells exploit their plasticity by metabolic signals, exosomal oncomiRs, paracrine factors and so on to push them into a pro-metastatic phenotype. Reprogrammed macrophages proceed to participate in detachment of tumor cells, resistance to anoikis, escaping across mesothelium and stimulating angiogenesis and lymphangiogenesis, but also instigate an immunosuppressive environment suppressing T cell activity and increasing chemoresistance. Important molecular players that we describe here are CCL2/CCR2 and CSF-1/CSF-1R signaling axes, the STAT3/STAT6/PI3K axis and a complement-driven switch of TAMs from a cathepsin (CTS)-high to complement component 1q(C1q)-high state that promotes immune evasion. We also discuss the role of exosome-mediated cross-talk and give an overview of novel therapies against macrophages such as blocking their recruitment, reprogramming their polarization or using chimeric antigen receptor macrophage (CAR-M) therapy, typically in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) or immune checkpoint inhibitors. Bringing together the latest advances, we highlight key gaps in our understanding and suggest a direction for dismantling the macrophage-orchestrated metastatic niche with the ultimate goal of improving outcomes of this devastating disease.
- 2 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1944126
Open AccessTumor-associated macrophages in gastric cancer peritoneal metastasis: orchestrating immune evasion, niche remodeling, and therapeutic resistance
Peritoneal metastasis is the most devastating form of progression of gastric cancer, characterized by strong immune suppressive properties and resistance to treatment. Tumor-associated macrophages (TAMs) are the main population of immune cells in the peritoneal cavity and participate in nearly every step of this process. In this Review, we focus on the two major origins of peritoneal macrophages (embryonic-derived GATA6+ resident cells and monocyte-derived CCR2+ cells), and we describe how gastric cancer cells exploit their plasticity by metabolic signals, exosomal oncomiRs, paracrine factors and so on to push them into a pro-metastatic phenotype. Reprogrammed macrophages proceed to participate in detachment of tumor cells, resistance to anoikis, escaping across mesothelium and stimulating angiogenesis and lymphangiogenesis, but also instigate an immunosuppressive environment suppressing T cell activity and increasing chemoresistance. Important molecular players that we describe here are CCL2/CCR2 and CSF-1/CSF-1R signaling axes, the STAT3/STAT6/PI3K axis and a complement-driven switch of TAMs from a cathepsin (CTS)-high to complement component 1q(C1q)-high state that promotes immune evasion. We also discuss the role of exosome-mediated cross-talk and give an overview of novel therapies against macrophages such as blocking their recruitment, reprogramming their polarization or using chimeric antigen receptor macrophage (CAR-M) therapy, typically in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) or immune checkpoint inhibitors. Bringing together the latest advances, we highlight key gaps in our understanding and suggest a direction for dismantling the macrophage-orchestrated metastatic niche with the ultimate goal of improving outcomes of this devastating disease.